Clinical Trial

Impact of Probiotics on Neuropathy Induced by Adjuvant Chemotherapy in Patients With Colon Cancer.

Study acronym: PROBIOCOL
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The pbjective of this study is to assess the impact of a multi-strain bacteria probiotic OXXYSLAB® on the reduction of oxaliplatin-induced peripheral neuropathy in patients with stage III colon cancer receiving FOLFOX or XELOX regimen in adjuvant treatment, assessed using the oxaliplatin-specific scale of Levi.
Trial Details
NCT Number NCT07733817
Lead Sponsor Centre Francois Baclesse
Conditions Colon Adenocarcinoma, Neuropathic Pain
Enrollment 130 participants
Start Date 2026-10-01
Primary Completion 2030-04-01 (estimated)
Study Completion 2036-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-30